EDIT vs BEAM
EDIT and BEAM side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEDITAS MEDICINE, INC. | BEAMBeam Therapeutics Inc. |
|---|---|---|
| Market cap | $415.43M | $2.80B |
| P/B | — | 2.63 |
| P/S | 10.3x | 20.2x |
| Revenue | — | $156.03M(TTM) |
| Revenue growth (YoY) | 25.4% | 120.0% |
| Net income | — | -$86.52M(TTM) |
| Earnings growth (YoY) | 32.5% | 78.8% |
| EPS, diluted | — | $-0.69(TTM) |
| EBIT margin | -394.9% | -274.6% |
| ROE | -152.0% | -7.5% |
| ROIC | — | -40.5% |
| 1y total return | -11.2% | +9.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: EDIT vs BEAM
| Metric | EDIT | BEAM |
|---|---|---|
| End value | $964 | $14.5K |
| Total return | -90.4% | +44.9% |
| CAGR | -29.3% | +5.7% |
| Volatility | 92.2% | 79.5% |
| Sharpe | 0.02 | 0.41 |
| Sortino | 0.02 | 0.63 |
| Max drawdown | -98.9% | -89.1% |
Based on 1694 common trading days, 2020-02-06 → 2026-11-02 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)